Clinical Trial News and Research

RSS

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

7 May 2013

Aptiv Solutions participates in 'Practice Adaptive Clinical Trials’ conference at Tokyo University

Aptiv Solutions, a biopharmaceutical and medical device development services company and pioneer in adaptive clinical trial design, simulation and execution, announces its participation in a prestigious conference on adaptive clinical trials, held at the University of Tokyo on May 10th 2013.

7 May 2013

Biocryst reports financial results for first quarter 2013

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2013.

7 May 2013

AUA and ASTRO release new guideline on adjuvant and salvage radiotherapy after prostatectomy

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.

7 May 2013

Implantation of new mechanical heart valve reduces anticoagulation therapy in AVR patients

For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation.

7 May 2013

Entremed reports patent issuance for its lead drug candidate ENMD-2076

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.

7 May 2013

New form of electroconvulsive therapy could prevent adverse cognitive side effects

Electroconvulsive therapy (ECT) is the most effective acute treatment for severe major depression. However, even with newer forms of ECT, there remains a significant risk of adverse cognitive effects, particularly memory problems.

7 May 2013

Aerobic exercise can help reduce breast cancer risk

Changes in estrogen breakdown, or metabolism, may be one of the mechanisms by which aerobic exercise lowers a woman's breast cancer risk, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 May 2013

Clinical trial recruits patients with lower back pain to investigate non-surgical treatment

A clinical trial being conducted at the University of British Columbia, sponsored by Active-O, is currently recruiting patients suffering from lower back pain caused by a contained herniated disc to investigate a new, non-surgical treatment.

6 May 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

3 May 2013

Men who take statins are less likely to die from prostate cancer, study finds

Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don't take such medication, according to study led by researchers at Fred Hutchinson Cancer Research Center.

3 May 2013

Study may help diagnose endometrial cancer and lead to new drug development

Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.

2 May 2013

Study brings opportunities of personalised therapy for breast cancer a step closer

A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

2 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

NeuroSigma receives Class 2 medical device license for Monarch eTNS System from Health Canada

NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its Monarch eTNS (external trigeminal nerve stimulation) System from Health Canada.

2 May 2013

Tips for prevention and early detection of skin cancer

According to the American Cancer Society, an estimated 82,770 Americans will be diagnosed this year with skin cancer, including melanoma. When left untreated, melanoma is the most dangerous and aggressive form of skin cancer, accounting for more than 9,000 of the 12,000-plus skin cancer deaths each year.

2 May 2013

Exposure to daylight helps protect children from myopia

Two new studies add to the growing evidence that spending time outdoors may help prevent or minimize nearsightedness in children. A study conducted in Taiwan, which is the first to use an educational policy as a public vision health intervention, finds that when children are required to spend recess time outdoors, their risk of nearsightedness is reduced.

2 May 2013

HCV screening of prison inmate drug users: an interview with Dr. Arthur Kim, Massachusetts General Hospital and Harvard Medical School

Prisoners overall have a very high rate of past or present injection drug use, which is a major risk factor for HCV infection due to repeated exposures to needles.

1 May 2013

Clinical Trial News and Research

Targacept reports net loss of $8.1 million in first quarter 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aptiv Solutions participates in 'Practice Adaptive Clinical Trials’ conference at Tokyo University

Biocryst reports financial results for first quarter 2013

AUA and ASTRO release new guideline on adjuvant and salvage radiotherapy after prostatectomy

Implantation of new mechanical heart valve reduces anticoagulation therapy in AVR patients

Entremed reports patent issuance for its lead drug candidate ENMD-2076

New form of electroconvulsive therapy could prevent adverse cognitive side effects

Aerobic exercise can help reduce breast cancer risk

Clinical trial recruits patients with lower back pain to investigate non-surgical treatment

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

Men who take statins are less likely to die from prostate cancer, study finds

Study may help diagnose endometrial cancer and lead to new drug development

Study brings opportunities of personalised therapy for breast cancer a step closer

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

NeuroSigma receives Class 2 medical device license for Monarch eTNS System from Health Canada

Tips for prevention and early detection of skin cancer

Exposure to daylight helps protect children from myopia

HCV screening of prison inmate drug users: an interview with Dr. Arthur Kim, Massachusetts General Hospital and Harvard Medical School

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer